Imatinib Drug Market Explores New Growth Opportunities by 2017– 2025
Growth in prevalence of cancer, increase in demand for target drug therapy, and patent expiry of imatinib drug are expected to drive the Imatinib Drug Market. According to the National Cancer Institute, in June 2017, it was estimated that there will be around 62,130 and 24,500 people with new cases and death due to leukemia, respectively, in the U.S.
View full press release